A post from @macroglide puts the Ozempic and Wegovy maker's US-listed stock at under $35 in 2026, down from roughly $144 at its high.
Recap by typeshit. Post by @macroglide on Instagram.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Morse says bar and restaurant workers have seen younger adults drink less, framing it as a broad change in the alcohol industry.
Bazaar India's new issue looks at collagen loss and skin laxity concerns tied to fast GLP-1 weight loss, and how beauty brands are responding.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
A short social post frames the semaglutide molecule as the start of a bigger business story for drugmakers, with a note that it is not medical advice.
Portela calls out people taking advice from TikTok comments to self-inject powders labeled not for human consumption, with melanotan as the example.
Loading…